Dr. Lior Shaltiel reports

NUREXONE LAUNCHES BIOPROCESS OPTIMIZATION INITIATIVE TO SUPPORT COMMERCIAL AND CLINICAL READINESS

Nurexone Biologic Inc. has commenced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.

Nurexone is collaborating with Austria-based Novasign GmbH on the initiative to apply Novasign's bioprocess modelling platform to Nurexone's proprietary exosome production process and assess opportunities to support process optimization and a planned technology transfer to Exo-Top Inc., the company's wholly owned U.S. subsidiary.

The project is designed to enhance process analysis, inform technology transfer planning and identify opportunities to improve manufacturing efficiency, while supporting consistent product characterization. Nurexone is sharing upstream bioprocess data for assessment by Novasign against predefined key performance indicators, including process efficiency and operating costs.

"During 2026, we are focused on advancing Nurexone's commercial and clinical readiness through continued progress in manufacturing, scientific development and regulatory advancement," said Dr. Lior Shaltiel, chief executive officer of Nurexone. "Manufacturing readiness extends beyond GMP production capacity. It also requires robust, well-understood processes that can be consistently reproduced and efficiently transferred to Exo-Top and, where applicable, a U.S. manufacturing partner. This project is intended to support that transfer."

"Nurexone's advanced exosome manufacturing activity and processes provide an excellent opportunity to demonstrate how structured bioprocess modelling with Novasign Studio can support technology transfer and process optimization," said Dr. Mark Duerkop, chief executive officer of Novasign. "Our aim is to generate actionable insights that can strengthen process understanding, identify efficiency opportunities and support effective technology transfer. Subject to the outcome of the initiative and the parties' further agreement, we also see potential to share selected learnings through a case study for the broader biologics manufacturing community."

Exo-Top was established as a core part of Nurexone's production and supply strategy, including supply of high-quality exosomes for the company's future therapeutic requirements and selected commercial opportunities. Additional background information on Nurexone's therapeutic and manufacturing strategy is available on the company's website.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the U.S. and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top to anchor its North American activity and growth strategy.

We seek Safe Harbor.